Pharmaceutical

Optofluidics, Inc. is a venture backed life-sciences company that is developing microfluidic and biophotonic nanomanipulation technologies for biological, material science, and pharmaceutical applications. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin NanoTechnology Institute. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Diamon Fusion International, Inc., a patented nanotechnology, improves and protects the surfaces of glass, tile, porcelain, granite, and most silica-based surfaces.

Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics.

Pulmatrix is developing new breakthrough therapies with the vision of fundamentally changing the way we treat, prevent and control infectious and progressive respiratory diseases.

Polychromix is a leader in miniature and portable analysis tools. The company’s innovative products enable the migration of traditional laboratory-based instrumentation from the lab to the point of need for fast, accurate, non-destructive material analysis.

Mersana Therapeutics employs its biodegradable polymer platform (Fleximer®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of therapeutic radiopharmaceuticals and targeted molecular imaging agents for use in oncology and cardiology.

Merrimack Pharmaceuticals are dedicated to the discovery and development of innovative therapies for the treatment of autoimmune disease and cancer. Merrimack is advancing a robust pipeline of clinical and early-stage biologics that represent the next generation of patient-directed, targeted therapies.

Masscal Scientific Instruments introduces a line of laboratory instruments which can measure moisture sorption, catalysis, curing and many other reactions of thin films and surfaces. The powerful, patented technology provides critical new capabilities for simultaneously measuring mass changes, reaction energy and film viscoelastic property with nanogram sensitivity. Materials are analyzed under precisely programmed environments of temperature, exposure times, humidity, or other gas compositions.